MagForce
Market Cap
€66.2m
Last Updated
2020/10/28 21:22 UTC
Data Sources
Company Financials +
Executive Summary
MagForce AG operates in the field of nanotechnology-based cancer treatment in Germany and Poland. More Details
Rewards
Risk Analysis
Snowflake Analysis
Exceptional growth potential and slightly overvalued.
Share Price & News
How has MagForce's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MF6's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-7.8%
MF6
-0.4%
DE Medical Equipment
-4.7%
DE Market
1 Year Return
-49.6%
MF6
23.9%
DE Medical Equipment
-3.8%
DE Market
Return vs Industry: MF6 underperformed the German Medical Equipment industry which returned 23.6% over the past year.
Return vs Market: MF6 underperformed the German Market which returned -3.8% over the past year.
Shareholder returns
| MF6 | Industry | Market | |
|---|---|---|---|
| 7 Day | -7.8% | -0.4% | -4.7% |
| 30 Day | 0% | 5.6% | -2.4% |
| 90 Day | -22.7% | -2.6% | -4.4% |
| 1 Year | -49.6%-49.6% | 25.7%23.9% | -0.8%-3.8% |
| 3 Year | -68.7%-68.7% | 178.3%171.8% | -4.5%-12.9% |
| 5 Year | -55.4%-55.4% | 316.3%298.7% | 15.5%-1.0% |
Price Volatility Vs. Market
How volatile is MagForce's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 months ago | Simply Wall St
MagForce (ETR:MF6) Is Making Moderate Use Of Debt8 months ago | Simply Wall St
MagForce (ETR:MF6) Is Carrying A Fair Bit Of Debt11 months ago | Simply Wall St
Does MagForce (ETR:MF6) Have A Healthy Balance Sheet?Valuation
Is MagForce undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MF6 (€2.39) is trading below our estimate of fair value (€16.03)
Significantly Below Fair Value: MF6 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MF6 is unprofitable, so we can't compare its PE Ratio to the DE Medical Equipment industry average.
PE vs Market: MF6 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MF6's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MF6 is overvalued based on its PB Ratio (4.5x) compared to the DE Medical Equipment industry average (4.2x).
Next Steps
Future Growth
How is MagForce forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
63.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MF6 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).
Earnings vs Market: MF6 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MF6's is expected to become profitable in the next 3 years.
Revenue vs Market: MF6's revenue (50.5% per year) is forecast to grow faster than the German market (6% per year).
High Growth Revenue: MF6's revenue (50.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MF6's Return on Equity is forecast to be very high in 3 years time (49.2%).
Next Steps
Past Performance
How has MagForce performed over the past 5 years?
-0.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MF6 is currently unprofitable.
Growing Profit Margin: MF6 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MF6 is unprofitable, and losses have increased over the past 5 years at a rate of 0.9% per year.
Accelerating Growth: Unable to compare MF6's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MF6 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.8%).
Return on Equity
High ROE: MF6 has a negative Return on Equity (-59.36%), as it is currently unprofitable.
Next Steps
Financial Health
How is MagForce's financial position?
Financial Position Analysis
Short Term Liabilities: MF6's short term assets (€1.6M) do not cover its short term liabilities (€6.5M).
Long Term Liabilities: MF6's short term assets (€1.6M) do not cover its long term liabilities (€15.4M).
Debt to Equity History and Analysis
Debt Level: MF6's debt to equity ratio (113.4%) is considered high.
Reducing Debt: Insufficient data to determine if MF6's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if MF6 has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MF6 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is MagForce current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MF6's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MF6's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MF6's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MF6's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MF6's dividend in 3 years as they are not forecast to pay a notable one for the German market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
8.0yrs
Average management tenure
CEO
Ben Lipps (80 yo)
7.08yrs
Tenure
Dr. Benjamin J. Lipps, also known as Ben, serves as Director and Chief Executive Officer at MagForce USA, Inc. He has been the Chairman of the Management Board and Chief Executive Officer at MagForce AG si ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Management Board & CEO | 7.08yrs | no data | no data | |
| CFO & Member of Management Board | 8yrs | no data | no data | |
| Chief Medical Officer & Member of Management Board | 8yrs | no data | no data | |
| Executive VP | no data | no data | no data | |
| Vice President of Communications & Investor Relations | 4.58yrs | no data | no data | |
| VP of Marketing & Sales and European Commercial Director | no data | no data | no data | |
| Medical Consultant | 9.92yrs | no data | no data |
8.0yrs
Average Tenure
63yo
Average Age
Experienced Management: MF6's management team is seasoned and experienced (8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
MagForce AG's company bio, employee growth, exchange listings and data sources
Key Information
- Name: MagForce AG
- Ticker: MF6
- Exchange: XTRA
- Founded: 1997
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: €66.215m
- Shares outstanding: 27.71m
- Website: https://www.magforce.com
Number of Employees
Location
- MagForce AG
- Max-Planck-Strasse 3
- Berlin
- Berlin
- 12489
- Germany
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MF6 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Sep 2007 |
| MF6 | XTRA (XETRA Trading Platform) | Yes | Common Stock | DE | EUR | Sep 2007 |
| MGFR.F | OTCPK (Pink Sheets LLC) | Yes | Common Stock | US | USD | Sep 2007 |
| 0W10 | LSE (London Stock Exchange) | Yes | Common Stock | GB | EUR | Sep 2007 |
Biography
MagForce AG operates in the field of nanotechnology-based cancer treatment in Germany and Poland. It offers NanoTherm therapy for the treatment of solid tumors; NanoTherm, a ferrofluid liquid containing su ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/28 21:22 |
| End of Day Share Price | 2020/10/28 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.